Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 5/20 | 0.34 |
| ▸ | CASP1 | P29466 | 5/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | CASP7 | P55210 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035335 | 0.89 | ERN1 (0.58) | ERN1BRAFKITUSP2CASP1 | |
| SCHEMBL25035463 | 0.88 | ERN1 (0.42) | ERN1BRAFRORCUSP2CASP1 | |
| SCHEMBL25035466 | 0.87 | ERN1 (0.51) | ERN1BRAFKITBRD4F2 | |
| SCHEMBL25035578 | 0.86 | RORC (0.39) | ERN1RORCBRD4USP2CASP1 | |
| SCHEMBL25035392 | 0.86 | ERN1 (0.41) | ERN1BRAFRORCUSP2CASP1 | |
| SCHEMBL25035661 | 0.85 | ERN1 (0.48) | ERN1RORCUSP2CASP1HIF1A | |
| SCHEMBL25035361 | 0.84 | BRAF (0.40) | ERN1BRAFRORCPIK3CAMTOR | |
| SCHEMBL22200612 | 0.84 | RORC (0.35) | ERN1BRAFRORCUSP2CASP1 | |
| SCHEMBL25035364 | 0.82 | ERN1 (0.42) | ERN1BRAFRORCF2PIK3CA | |
| SCHEMBL25035369 | 0.82 | ERN1 (0.57) | ERN1BRAFUSP2CASP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885BRAF 563/4885RORC 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.